Research Article

Therapeutic Effects of VEGF Gene-Transfected BMSCs Transplantation on Thin Endometrium in the Rat Model

Zhao Jing,1 Yan Yi,1 Huang Xi,1 Lun-Quan Sun,2 and Li Yanping1

1Reproductive Medicine Center, Xiangya Hospital, Central South University, Changsha, Hunan, China
2Center for Molecular Medicine, Xiangya Hospital, Central South University, Hunan, China

Correspondence should be addressed to Li Yanping; lyp7798@126.com

Received 21 June 2018; Accepted 2 September 2018; Published 30 October 2018

Academic Editor: Andrea Ballini

Copyright © 2018 Zhao Jing et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Bone mesenchymal stem cells (BMSCs) transplantation has a therapeutic effect on the thin endometrium in animal researches and clinical trials. The present study aims at assessing whether transplantation of VEGF-transfected BMSCs (VEGF-BMSCs) have a better therapeutic effect on endometrial regeneration and endometrial receptivity compared with BMSCs therapy alone.

Methods. Sprague-Dawley (SD) rats were used in the study. Thin endometrium model was established with 95% ethanol injection into uterine. VEGF-BMSCs or BMSCs was transplanted via tail vein IV injection. Endometrial thickness, morphology, and pinopodes were assessed by hematoxylin and eosin (HE) staining and scanning electron microscope (SEM). The proteins and mRNAs expressions of markers for endometrial cells and endometrial receptivity were measured after treatment. The fertility testing was done to assess the embryo implantation efficiency.

Results. VEGF-BMSCs transplantation significantly increased endometrial thickness compared with the BMSCs group and the control group. There was no significant difference in endometrial thickness between VEGF-BMSCs group and sham operation group. Importantly, in protein level, expressions of cytokeratin, vitamin, VEGF, LIF, and integrin ανβ3 in VEGF-BMSC group were increased dramatically compared with those of the control group and BMSC group both 4 days and 8 days after stem cells transplantation. Accordingly, mRNA expression of LIF and integrin ανβ3 was significantly upregulated compared with those of the control group and BMSC group both 4 and 8 days after treatment. The pinopodes were developed better in the VEGF-BMSCs group and the sham operation group compared with BMSCs group and the control group. The number of embryo implantation is largest in the sham operation group, followed by VEGF-BMSCs group, BMSCs group, and the control group.

Conclusions. Transplantation of VEGF gene-transfected BMSCs may be a better therapeutic treatment for thin endometrium than stem cell therapy alone.

1. Introduction

A thin endometrium often means impaired endometrial receptivity, which has been well recognized as a critical factor in implantation failure [1–4]. At present, there was no uniform definition for "thin endometrium". A number of studies suggested that a minimal endometrial thickness of 6 mm is required for embryo implantation [5]. Several treatments, such as estrogen, aspirin, pentoxifylline, and endometrial injury, have been tried to improve the regeneration of the endometrium. However, improvement was not very obvious with the available treatments [6–8]. It is still a big challenge to find a useful treatment for thin endometrium [9].

Until now, the most promising treatment for thin endometrium or Asherman syndrome (AS) seems to be the stem-cell therapy. There have been many animal and human reports about the treatment effect of stem cells transplantation on the thin endometrium. A number of animal experiments showed that the thin endometrium was significantly improved after stem cells transplantation [10–13]. Clinical reports showed that infertile women with thin endometrium or AS had a significant increase in endometrial thickness after stem cells treatment and enhanced pregnancy rates [14–17].

It was reported that thin endometrium pathophysiologic features were as follows: increased flow impedance of radial arteries has a detrimental effect on the glandular epithelium,
leading to a decreased level of vascular endothelial growth factor (VEGF). At last, poor vascular development and impaired blood flow of the endometrium were caused [18]. VEGF was an angiogenesis factor and play a critical role in angiogenesis via branching of old blood vessels or sprouting of new blood vessels. Recently, stem cells transplantation has been discussed as a treatment for thin endometrium. So, the present study aimed at investigating whether the VEGF gene-transfected BMSCs (VEGF-BMSCs) have a better effect on the thin endometrium.

2. Materials and Methods

2.1. Animals. Seven–nine weeks Sprague-Dawley (SD) rats weighing 150–250 g were used in the experiments. All animal experiments were performed in strict line with the “National Institutes of Health Guide for the Care and Use of Laboratory Animals”. The present study was reviewed and approved by the Institutional Review Board and the Ethics Committee of Xiangya Hospital, Central South University.

2.2. BMSCs’ Collection and Culture. Bone marrow was aspirated and prepared from the femurs and tibia of an adult, male/female, SD rats. The bone marrow was digested, cultured, and filtered according to a previous study [19]. When reaching at least 80% confluence, the stem cells were collected with 0.05% trypsin-EDTA (Gibco). BMSCs were cultured at a density of 3000 to 6000/cm², and the fourth to sixth passages BMSCs were used for transfection and transplantation.

2.3. Plasmid Preparation and Transfection of Rat BMSC. Human VEGF₁₆₅ was integrated into the pcR3.1 plasmid, which was published previously. 1 μg of plasmid DNA of hVEGF₁₆₅ was used for transfection per 100,000 cells, and the empty pcR3.1 combined with 3 μL of metafectene was used as control group per 100,000 cells. These cells were transferred to BMSCs culture medium 6 hours later and were kept overnight. Before transplantation, 5*10⁶ of the stem cells was suspended in saline at a concentration of 50,000 cells/μL.

2.4. Groups. Standardized laboratory conditions, including air-condition rooms and plenty of water and food, were applied to keep the rats. According to our preliminary study, a thin endometrium rat model was built by injecting anhydrous ethanol into the uterus cavity of rats [20]. One hundred rats were divided into four groups randomly, which included control group (operation without modeling, n = 25), BMSC group (injected BMSCs into tail vein 6–8 hours after modeling, n = 25), VEGF-BMSC group (injected VEGF-BMSCs into tail vein 6–8 hours after modeling, n = 25), and sham operation group (operation without modeling, n = 25).

For further research, uteri of rats were sectioned and stored in liquid nitrogen and/or formalin.

2.5. Hematoxylin and Eosin (HE) Staining. HE staining was performed according to a previous study [21]. The slides with 5 μm thickness were completely covered in xylene twice and rehydrated in a series of ethanol with gradually decreased concentration. The slides were rinsed with deionized demineralized water, dyed in hematoxylin for about 50 seconds, rinsed with deionized demineralized water once again, and at last dyed in eosin for 3 seconds. The slides of the endometrium were dehydrated with a series of ethanol in xylene and mounted with Permumount mounting medium after the color reaction. The endometrial morphology and the endometrial thickness were examined and compared between groups.

2.6. Immunohistochemistry. For immunohistochemistry, the uterine were stored in 4% parafomaldehyde and embedded in paraffin. Serial slides with about 6 μm were prepared, deparaffinized in xylene, rehydrated with different concentrations ethanol, and rinsed with water. Endogenous peroxidase was blocked with 3% hydrogen peroxide. Slides were treated with chondroitin ABC lyase (0.15 U/mL) and blocked with 10% normal goat serum for 1 hour. Expressions of cytokeratin, vimentin, integrin ανβ₃, and leukemia inhibitory factor (LIF) proteins were performed by incubating slides of rat uter with rabbit polyclonal antibodies against cytokeratin, vimentin, integrin ανβ₃, and LIF overnight at 4°C. Slides were incubated with secondary antibodies at 1:3000 dilution followed by DAB solution for 1 hour. Then, slides were briefly stained with hematoxylin solution (15 seconds) (Gill no. 3; Sigma) and evaluated by a microscope (Nikon).

2.7. Western Blotting. Total protein was extracted from uterine tissues according to the protocol, and the concentration of protein was confirmed with a Precision Red Assay (Cyto-skeleton Inc.). Equal amounts of protein were stained with loading dye and separated with 12% SDS-PAGE. Protein was then transferred to polyvinylidene difluoride (PVDF) membrane and was incubated with 5% bovine serum albumin (BSA). The membrane was exposed to anti-VEGF antibody (1:500), anti-cytokeratin antibody (1:500), anti-vimentin antibody (1:500), anti-integrinανβ₃ antibody (1:300), anti-integrinβ₃ antibody (1:300), and anti-LIF antibody (1:300) overnight. The blots were washed with tris-buffer saline and incubated with secondary anti-rabbit IgG (1:3000; Cell Signaling Technology) for 1 hour at room temperature. The protein content was detected using SuperSignal West Pico (Pierce Biotechnology). Anti-β-actin antisera (Sigma) was used as an internal standard between groups.

2.8. Real-Time PCR. Total RNA was collected from the harvested uteri by the use of an extraction reagent (Trizol; Gibco) and was dissolved in water treated with diethylpyrocarbonate, and the concentration was measured by a spectrophotometer (UV–1601). In order to determine a constant expression of a housekeeping gene in the RNA extractions, the real-time PCR of GAPDH was also performed. Any possible DNA contamination was removed with DNase I (0.2 U/μL; Ambion). Quantitative PCR reaction was performed with Biosystems 7500 Fast Real-Time PCR system and Taqman.
increased endometrial thickness. The endometrium of the structure, with more endometrial glands, capillaries and layer of the VEGF-BMSC group showed a relatively intact compared with that of the control group. The endometrial endometrial glands, and a signifi

**3. Results**

3.1. BMSC Phenotype. The BMSCs, obtained from rat bone marrow aspirates, were grown in the cultural medium as previously published. FACS analysis showed that CD90 and CD73 were expressed in BMSCs, whereas hematopoietic markers CD45 and CD34 were negative. The BMSCs had the capability to differentiate toward adipocytes and osteoblasts.

3.2. Histopathological Observations. Rat in BMSCs and VEGF-BMSCs group had a significantly larger number of endometrial glands, and a significant thicker endometrium compared with that of the control group. The endometrial layer of the VEGF-BMSC group showed a relatively intact structure, with more endometrial glands, capillaries and increased endometrial thickness. The endometrium of the control group was totally damaged, showing extensive coagulation necrosis, cell apoptosis in the nearly whole layer of endometrium and parts of the myometrium layer.

The endometrial thickness of the control group, BMSC group, VEGF-BMSC group, and sham operation group were as follows: 218.7 ± 20.6 µm, 598.7 ± 37.7 µm, 658.0 ± 40.0 µm, and 682.3 ± 38.2 µm, respectively. The VEGF-BMSC group had an obvious thicker endometrial lining compared with that of the control group and the BMSC group, and there was no significant difference between the VEGF-BMSC group and the sham operation group (Figure 1).

3.3. Protein Expression of VEGF, Cytokeratin, Vimentin, Integrin ανββ, and LIF. Immunohistochemical results demonstrated that cytokeratin, integrin ανββ, and LIF were mainly expressed in the cytoplasm of the endometrial epithelial cells, and vimentin was mainly localized in the cytoplasm of endometrial stromal cells. The expression of cytokeratin, vimentin, integrina,β3, and LIF in the VEGF-BMSC group and BMSC group were significantly stronger than those of the control group and were slightly weaker than those of the sham operation group without significance. (Figure 2, Supplemental Figure 1).

Western Blotting was applied to exam the expression of these proteins in the endometrium 4 days and 8 days after stem cells transplantation. Vimentin, integrin ανββ, and LIF protein expressions were gradually increased in the control, BMSC, VEGF-BMSC, and sham operation groups, respectively. VEGF-BMSC group showed a significantly higher expression of these four proteins compared with those of control group (P < 0.05). VEGF expression level was the highest in the VEGF-BMSC group, followed by BMSC group, sham operation group, and control group. The cytokeratin expression level in the VEGF-BMSC group was slightly higher than that of the BMSC group and sham operation group without a significant difference and was significantly higher compared with the control group. When compared day 4 with day 8 after stem cells transplantation, there was no significant difference in the expressions of those proteins. (Figure 3, Supplemental Figure 2).

3.4. mRNA Expression of VEGF, Integrin ανββ, and LIF. mRNA expressions of endometrial receptivity's markers 4 and 8 days after treatment are shown in Figure 4 and Supplemental Figure 3. The VEGF-BMSC group exhibited a significantly higher expression of VEGF mRNA than the BMSC group and control group and a similar level with the sham operation group. The LIF mRNA expression in the VEGF-BMSC group was significantly higher than that of the BMSC group and control group and was similar with that of the sham operation group. The integrin αν ββ mRNA expressions in the VEGF–BMSC group and BMSC group were similar, which were significantly higher when compared with the control group.

3.5. Pinopodes of the Endometrium. In the control group, the endometrium is thin. The microvilli were abundant, and no developed pinopodes in luminal cells were observed. In the BMSCs group and VEGF–BMSCs group, the microvilli gradually decreased in number and length. Smooth and slender
membrane projections were formed from the cell apex and were transformed to pinopodes. We can observe that the pinopodes were developing and some of them had short microvilli in their surface in VEGF-BMSCs group and sham operation group. There were no significant differences between VEGF-BMSCs group and sham operation group in the number of pinopodes (Figure 5).

3.6. Embryo Implantation after VEGF-BMSCs/BMSCs Transplantation. Embryo implantation efficiency is the best index to assess the therapeutic effect of VEGF-BMSCs/BMSCs transplantation. In order to detect the effect of BMSCs/VEGF-BMSCs on the thin endometrium and endometrial receptivity, we looked at the embryo implantation efficiency in the different groups of rats. The sham operation group showed the greatest embryo implantation efficiency, followed by VEGF-BMSCs group, BMSC group, and control group. Sham operation group showed a significantly increased embryo implantation efficiency compared with BMSCs group and control group, and there was no significant difference between the sham operation group and VEGF-BMSCs group. (Figure 6, Supplemental Figure 4).

4. Discussion

There are many experimental studies showing the beneficial effects of VEGF gene-transfected stem cells transplantation on many disorders, such as bone defects, stroke, myocardial infarction, acute kidney injury, and bronchopulmonary dysplasia. [22–25].

At present, there are no reports about the VEGF gene-transfected stem cells transplantation as the treatment for thin endometrium or AS. As we all know, angiogenesis is necessary for the regeneration of endometrium after menstruation and plays a crucial role in the development of endometrial receptivity for successful embryo implantation [26, 27]. A lot of studies have explored the regulation of endometrial angiogenesis and showed that the vascularization of the endometrium was regulated by VEGF, which was expressed in the human endometrium [28–32]. Therefore,
Figure 2: Protein expression of markers for endometrial cells and endometrial receptivity with immunohistochemistry. The expression of cytokeratin, vimentin, integrin-α₃β₃, and LIF in the VEGF-BMSC group and BMSC group was significantly stronger than those of the control group and were slightly weaker than those of the sham operation group without significance.

Figure 3: Protein expression of markers for endometrial cells and endometrial receptivity with Western blotting. (A, B, C, D) represent the control group, BMSC group, VEGF-BMSC group, and sham operation group 4 days after treatment, respectively. (A‘, B‘, C‘, D‘) mean these four groups 8 days after treatment. Vimentin, integrin α₃β₃, and LIF protein expressions were gradually increased in the control, BMSC, VEGF-BMSC, and sham operation groups, respectively. VEGF-BMSC group showed a significantly higher expression of these four proteins compared with those of control group (P < 0.05). VEGF expression level was the highest in the VEGF-BMSC group, followed by BMSC group, sham operation group, and control group. The cytokeratin expression level in the VEGF-BMSC group was significantly higher compared with the control group. When compared day 4 with day 8 after stem cells transplantation, there was no significant difference in the expressions of those proteins.
the pathophysiology of thin endometrium is damaged angiogenesis and decreased uterine blood flow.

Our previous studies have proved that BMSC transplantation could promote the growth of thin endometrium and improve the endometrial receptivity [12, 13]. It was supposed that VEGF gene-transfected BMSC would be a better therapy for thin endometrium. The present study is the first experiment, which assessed the effect of VEGF-BMSCs transplantation on thin endometrium in a rat model.

In our study, we showed that the rats in the VEGF-BMSC group had a thicker endometrium than those in the control group and BMSC group, and the expression of cytokeratin and vimentin in the VEGF-BMSC group was stronger than that in the control group and BMSC group. What we found indicated that IV infusion of VEGF-BMSCs promotes the regeneration of the endometrial cells and have a stronger therapeutic effect for thin endometrium.

We not only examined the endometrial regeneration but also assessed the endometrial receptivity. The present study found that the mRNA and protein expressions of integrin $\alpha_\nu\beta_3$ and LIF have significantly decreased in the thin endometrium rats without BMSC or VEGF-BMSC transplantation, and the BMSC/VEGF-BMSC treatment almost normalized the expression of integrin $\alpha_\nu\beta_3$ and LIF. As important regulators of endometrial function, integrin and LIF are considered to be the markers for endometrial receptivity and play a critical role in embryo implantation [33, 34]. Integrins belong to transmembrane glycoproteins family, and integrin $\alpha_\nu\beta_3$, $\alpha_\beta_1$, and $\alpha_\beta_3$ were found to be coexpressed in endometrium on days 20–24 of the human menstrual cycle [35, 36]. These three integrins have been considered as endometrial receptivity markers, and $\alpha_\nu\beta_3$ was found to be important in the course of embryo attachment. LIF receptors are expressed by the blastocyst as well as the endometrium, with maximum expression of LIF mRNA and protein occurring in endometrial epithelium during the implantation window, so it was considered to play an important role in implantation [37].

In addition to the protein marker of endometrial receptivity, we also observed the pinopodes, which are smooth mushroom-like projections that arise from the apical surface of the endometrium and are considered as endometrial

![Figure 4: mRNA expressions of endometrial receptivity’s markers 4 and 8 days after treatment. (A, B, C, D) represent control group, BMSC group, VEGF-BMSC group, and sham operation group, respectively. The VEGF-BMSC group exhibited a significantly higher expression of VEGF mRNA than the BMSC group and control group. The LIF mRNA expression in the VEGF-BMSC group was significantly higher than that of the BMSC group and control group and was similar with that of the sham operation group. The integrin $\alpha_\nu\beta_3$ mRNA expressions in the VEGF-BMSC group and BMSC group were similar, which were significantly higher when compared with the control group.](image-url)
receptivity marker [38]. The pinopodes are observed for a short time period, 24 to 48 hours, during implantation in mammals [39], depending on the ovarian hormones, especially progesterone. In the rat endometrium, the appearance of pinopodes clearly demarcates the window of receptivity with a rise in numbers on day 4 of pregnancy, abundance on day 5 [40], and rapid decline on day 6 [38, 41]. The results showed that there were well-developed pinopodes in the sham operation group, BMSCs group, and VEGF-BMSCs group, and there was no pinopode in the control group. The function of pinopodes is not clear. The surfaces of pinopodes may have some receptors for adhesion molecules, which are essential for embryo implantation [42]. A vitro study observed the embryo attachment to endometrial epithelial cell and proposed that pinopode improve the attachment of blastocysts to endometrium during the processes of implantation [43].

Accordingly, the fertility testing demonstrated that embryo implantation efficiency is significantly higher in BMSCs group and VEGF-BMSCs group compared with the control group. The study has confirmed that UC-MSCs can promote endometrial proliferation and recover the endometrial embryo implantation ability [44]. This is consistent with our findings. We found that the VEGF-BMSC transplantation not only promote the endometrial regeneration but also improve the endometrial receptivity, showing a better therapeutic effect compared with BMSCs treatment alone.

Our data, which show a stronger mRNA and protein expressions of cytokeratin, vimentin, integrin ανβ3, and LIF, indicated that stem cells transplantation might not only bring

Figure 5: Scanning electron microscopy (×1000, ×2000) of the endometrial surface.
beneficial effect on the endometrial regeneration but also bring good for endometrial receptivity improvement.

For Asherman’s syndrome or thin endometrium, stem cells transplantation seems to be the most promising treatment. Several animal studies showed a significant enhancement of endometrial thickness and receptivity after MSCs transplantation into a rat model of thin endometrium [10–13]. All experimental groups showed an improvement in the fibrosis level and elucidated regenerative capabilities of BMSCs when thin endometrium rats were infused with BMSCs [12, 13]. It was found that transplanted cells could migrate to the injured uterus after intrauterine or tail vein injection. So migration to the injured sites and/or immune-regulation effect was the possible mechanisms of stem cells’ effect [10, 11]. Stem cells not only promoted endometrial cell differentiation/proliferation and vascularization [10] but also decreased fibrosis, which ensured tissue repair. At last, stem cell transplantation restored the endometrial function and improved the fertility rate eventually [11].

Stem cells treatment for thin endometrium or AS was also applied in human. The first report of stem cell treatment for human was published in 2011 [14]. Autologous stromal stem cells were transplanted into the endometrial cavity with refractory thin endometrium (3.6 mm) [14]. At last, the endometrium was appropriate for embryo implantation. Another study [16] investigated six women with AS and found that transplantation of autologous BMSCs significantly improved the embryo implantation. Subsequently, Santamaria et al. [15] transplanted autologous CD133+ BMSCs into 11 AS and 5 endometrial atrophies (ET < 5 mm) women and showed endometrial functional restoration two months after cell therapy. Inspiringly, a recent study [17] found that transplantation of autologous menstrual blood-derived stromal cells (menSCs) could increase the endometrial thickness of severe AS; suggested autologous menSCs transplantation might be the most possible choice for severe AS. All of the above studies indicated that stem cells treatment was effective in endometrial regeneration.

The present study firstly explored the effect of VEGF gene-transfected BMSC transplantation on the thin endometrium and showed inspiring results. However, there were also some limitations. Firstly, the present study did not investigate the effect mechanism of VEGF-BMSCs treatment for thin endometrium. Secondly, the safety of VEGF gene-transfected BMSCs transplantation is not clear, so there is a long way to go before clinical application. Thirdly, the present only evaluated the endometrial regeneration and endometrial receptivity and did not observe the embryo implantation and pregnancy after treatment.

5. Conclusions

In conclusion, VEGF gene-transfected BMSCs transplantation would be a better therapy for thin endometrium than BMSCs transplantation alone. Further studies, which assess the safety of VEGF-BMSC treatment, the mechanisms of its effect, are needed in the future.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

Rat protocols were approved by the Animal Experimental and Welfare Ethics Committee of Central South University (2015007).

Conflicts of Interest

No conflict of interest with the submission of this manuscript.

Authors’ Contributions

Zhao J. and Li Y. P. contributed to designing the experiment. Zhao J. and Yan Y. contributed to the conducting the animal experiment, acquiring and analysis the data. Huang X. participated in the revision of the article. All the authors contributed to the final approval of the article.

Acknowledgments

The authors thank Dr. Yi Ke, who works in the State Laboratory of Medical Genetics, Central South University of the People’s Republic of China, for his great help on the experiments, and also thank everyone in the Reproductive Medicine Center of Xiangya Hospital, Central South University, for their scientific advice and encouragement. This work was supported by the National Natural Science Foundation of China (Grant No. 81401269).
Supplementary Materials

Figure S1: AOD of markers for endometrial cells and endometrial receptivity with immunohistochemistry. A, B, C, D represent the control group, BMSC group, VEGF-BMSC group, and sham operation group. Figure S2: relative level of markers for endometrial cells and endometrial receptivity with Western blotting. A, B, C, D represent the control group, BMSC group, VEGF-BMSC group, and sham operation group 4 days and 8 days after treatment. Figure S3: amplification curves, melting curves, and standard curves of PCR. Figure S4: embryo implantation efficiency of the control group, BMSC group, VEGF-BMSC group, and sham operation. (Supplementary Materials)

References

[1] H. I. Abdalla, A. A. Brooks, M. R. Johnson, A. Kirkland, A. Thomas, and J. W. Studd, "Endometrial thickness: a predictor of implantation in ovum recipients?,” Human Reproduction, vol. 9, no. 2, pp. 363–365, 1994.

[2] V. Alam, L. Bernardini, J. Gonzales, R. H. Asch, and J. P. Balmaceda, "A prospective study of echographic endometrial characteristics and pregnancy rates during hormonal replacement cycles,” Journal of Assisted Reproduction and Genetics, vol. 10, no. 3, pp. 215–219, 1993.

[3] Y. Gonen, R. F. Casper, W. Jacobson, and J. Blankier, "Endometrial thickness and growth during ovarian stimulation: a possible predictor of implantation in in vitro fertilization,” Fertility and Sterility, vol. 52, no. 3, pp. 446–450, 1989.

[4] K. S. Richter, K. R. Bugge, J. G. Bromer, and M. J. Levy, "Relationship between endometrial thickness and embryo implantation, based on 1,294 cycles of in vitro fertilization with transfer of two blastocyst-stage embryos,” Fertility and Sterility, vol. 87, no. 1, pp. 53–59, 2007.

[5] H. Shapiro, C. Cowell, and R. Casper, "The use of vaginal ultrasound for monitoring endometrial preparation in a donor oocyte program,” Fertility and Sterility, vol. 59, no. 5, pp. 1055–1058, 1993.

[6] B. S. Hurst, J. T. Bohjwani, P. B. Marshburn, M. A. Papadakis, T. A. Loeb, and M. L. Matthews, "Low-dose aspirin does not improve ovarian stimulation, endometrial response, or pregnancy rates for in vitro fertilization,” Journal of Experimental & Clinical Assisted Reproduction, vol. 2, no. 1, p. 8, 2005.

[7] G. Sher and J. D. Fisch, "Effect of vaginal sildenafil on the outcome of in vitro fertilization (IVF) after multiple IVF failures attributed to poor endometrial development,” Fertility and Sterility, vol. 78, no. 5, pp. 1073–1076, 2002.

[8] A. A. Okusami, M. E. Moore, J. M. Hurwitz, and S. S. Richlin, "A case series of patients with endometrial insufficiency treated with pentoxifylline and alpha-tocopherol,” Fertility and Sterility, vol. 88, article $200$, 2007.

[9] O. Lebovitz and R. Orvieto, "Treating patients with “thin” endometrium – an ongoing challenge,” Gynecological Endocrinology, vol. 30, no. 6, pp. 409–414, 2014.

[10] I. Cervello, C. Gil-Sanchis, X. Santamaria et al., "Human CD133+ bone marrow-derived stem cells promote endometrial proliferation in a murine model of Asherman syndrome,” Fertility and Sterility, vol. 104, no. 6, pp. 1552–1560.e3, 2015.

[11] F. Alawadhi, H. Du, H. Cakmak, and H. S. Taylor, "Bone marrow-derived stem cell (BMDSC) transplantation improves fertility in a murine model of Asherman’s syndrome,” PLoS One, vol. 9, no. 5, article e96662, 2014.

[12] J. Zhao, Q. Zhang, Y. G. Wang, and Y. P. Li, "Rat bone marrow mesenchymal stem cells improve regeneration of thin endometrium in rat,” Fertility and Sterility, vol. 101, no. 2, pp. 587–594.e3, 2014.

[13] J. Zhao, Q. Zhang, Y. G. Wang, and Y. P. Li, "Uterine infusion with bone marrow mesenchymal stem cells improves endometrium thickness in a rat model of thin endometrium,” Reproductive Sciences, vol. 22, no. 2, pp. 181–188, 2015.

[14] C. B. Nagori, S. Y. Panchal, and H. Patel, "Endometrial regeneration using autologous adult stem cells followed by conception by in vitro fertilization in a patient of severe Asherman’s syndrome,” Journal of Human Reproductive Sciences, vol. 4, no. 1, pp. 43–48, 2011.

[15] X. Santamaria, S. Cabanillas, I. Cervello et al., "Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman’s syndrome and endometrial atrophy: a pilot cohort study,” Human Reproduction, vol. 31, no. 5, pp. 1087–1096, 2016.

[16] N. Singh, S. Mohanty, T. Seth, M. Shankar, S. Bhaskaran, and S. Dharmendra, "Autologous stem cell transplantation in refractory Asherman’s syndrome: a novel cell based therapy,” Journal of Human Reproductive Sciences, vol. 7, no. 2, pp. 93–98, 2014.

[17] J. Tan, P. Li, Q. Wang et al., "Autologous menstrual blood-derived stromal cells transplantation for severe Asherman’s syndrome,” Human Reproduction, vol. 31, no. 12, pp. 2723–2729, 2016.

[18] I. Miwa, H. Tamura, A. Takasaki, Y. Yamagata, K. Shimamura, and N. Sugino, "Pathophysiologic features of “thin” endometrium,” Fertility and Sterility, vol. 91, no. 4, pp. 998–1004, 2009.

[19] G. Munoz-Elias, D. Woodbury, and J. B. Black, "Rat stromal cells, mitosis, and neuronal differentiation: stem cell and precursor functions,” Stem Cells, vol. 21, no. 4, pp. 437–448, 2003.

[20] J. Zhao, H. Gao, and Y. P. Li, "Development of an animal model for thin endometrium using 95% ethanol,” Journal of Fertilization: In vitro, vol. 2, no. 4, 2012.

[21] W. Guo, H. Wang, S. Zou et al., "Bone marrow stromal cells produce long-term pain relief in rat models of persistent pain,” Stem Cells, vol. 29, no. 8, pp. 1294–1303, 2011.

[22] F. Geiger, M. Beverungen, H. Lorenz, J. Wieland, M. Feher, and N. Sugino, "Pathophysiological features of "thin" endometrium,” Fertility and Sterility, vol. 87, no. 5, pp. 313–317, 2007.

[23] M. H. Maurer, C. Thomas, H. F. Burgers, and W. Kuschinsky, "Transplantation of adult neural progenitor cells transfected with vascular endothelial growth factor rescues grafted cells in the rat brain,” International Journal of Biological Sciences, vol. 4, pp. 1–7, 2008.

[24] B. Chen, Q. Zeng, M. Lang, and S. Guan, "Transplantation of exogamous mesenchymal stem cells with transferred vascular endothelial growth factor gene applied for treatment of acute myocardial infarction in rat,” Basic and Clinical Medicine, vol. 25, pp. 529–533, 2005.

[25] F. Togel, P. Zhang, Z. Hu, and C. Westenfelder, "VEGF is a mediator of the renoprotective effects of multipotent marrow
stromal cells in acute kidney injury,” *Journal of Cellular and Molecular Medicine*, vol. 13, no. 8b, pp. 2109–2114, 2009.

[26] S. K. Smith, “Angiogenesis and implantation,” *Human Reproduction*, vol. 15, pp. 59–66, 2000.

[27] S. K. Smith, “Angiogenesis, vascular endothelial growth factor and the endometrium,” *Human Reproduction Update*, vol. 4, no. 5, pp. 509–519, 1998.

[28] S. Kashida, N. Sugino, S. Takiguchi et al., “Regulation and role of vascular endothelial growth factor in the corpus luteum during mid-pregnancy in rats,” *Biology of Reproduction*, vol. 64, no. 1, pp. 317–323, 2001.

[29] A. M. Sharkey, K. Day, A. McPherson et al., “Vascular endothelial growth factor expression in human endometrium is regulated by hypoxia,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 85, no. 1, pp. 402–409, 2000.

[30] J. L. Shifren, J. F. Tseng, C. J. Zaloudek et al., “Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 81, no. 8, pp. 3112–3118, 1996.

[31] N. Sugino, S. Kashida, A. Karube- Harada, S. Takiguchi, and H. Kato, “Expression of vascular endothelial growth factor (VEGF) and its receptors in human endometrium throughout the menstrual cycle and in early pregnancy,” *Reproduction*, vol. 123, no. 3, pp. 379–387, 2002.

[32] D. S. Torry, V. J. Holt, J. A. Keenan, G. Harris, M. R. Caudle, and R. J. Torry, “Vascular endothelial growth factor expression in cycling human endometrium,” *Fertility and Sterility*, vol. 66, no. 1, pp. 72–80, 1996.

[33] D. S. Perrier, R. C. Charlet, F. Goffin, M. Foidart, and V. Geenen, “The implantation window,” *Journal de Gynécologie, Obstétrique et Biologie de la Reproduction*, vol. 31, pp. 440–455, 2002.

[34] A. A. Acosta, L. Elberger, M. Borghi et al., “Endometrial dating and determination of the window of implantation in healthy fertile women,” *Fertility and Sterility*, vol. 73, no. 4, pp. 788–798, 2000.

[35] B. A. Lessey, A. J. Castelbaum, L. Wolf et al., “Use of integrins to date the endometrium,” *Fertility and Sterility*, vol. 73, no. 4, pp. 779–787, 2000.

[36] J. Wang and D. R. Armant, “Integrin-mediated adhesion and signaling during blastocyst implantation,” *Cells, Tissues, Organs*, vol. 172, no. 3, pp. 190–201, 2002.

[37] A. Makker, I. Tandon, M. M. Goel, M. Singh, and M. M. Singh, “Effect of ormeloxifene, a selective estrogen receptor modulator, on biomarkers of endometrial receptivity and pinopode development and its relation to fertility and infertility in Indian subjects,” *Fertility and Sterility*, vol. 91, no. 6, pp. 2298–2307, 2009.

[38] M. M. Singh, S. C. Chauhan, R. N. Trivedi, S. C. Maitra, and V. P. Kamboj, “Correlation of pinopod development on uterine luminal epithelial surface with hormonal events and endometrial sensitivity in rat,” *European Journal of Endocrinology*, vol. 135, no. 1, pp. 107–117, 1996.

[39] G. Nikas, P. Drakakis, D. Loutradus et al., “Implantation: uterine pinopodes as markers of the ‘implantation window’ in cycling women receiving exogenous oestradiol and progesterone,” *Human Reproduction*, vol. 10, no. 5, pp. 1208–1213, 1995.

[40] A. Psychoyos and P. Mandon, “Study of the surface of the uterine epithelium by scanning electron microscope. Observations in the rat at the 4th and 5th day of pregnancy,” *Comptes rendus hebdomadaires des séances de l’Académie des sciences. Series D: Sciences naturelles*, vol. 272, pp. 2723–2725, 1971.

[41] C. E. Quinn, J. Detmar, and R. F. Casper, “Pinopodes are present in Lif null and Hoxa10 null mice,” *Fertility and Sterility*, vol. 88, no. 4, pp. 1021–1028, 2007.

[42] D. Martel, R. Frydman, M. Glissant, C. Maggioni, D. Roche, and A. Psychoyos, “Scanning electron microscopy of postovulatory human endometrium in spontaneous cycles and cycles stimulated by hormone treatment,” *The Journal of Endocrinology*, vol. 114, no. 2, pp. 319–328, 1987.

[43] U. Bentin-Ley, A. Sjögren, L. Nilsson, L. Hamberger, J. F. Larsen, and T. Horn, “Presence of uterine pinopodes at the embryo-endometrial interface during human implantation in vitro,” *Human Reproduction*, vol. 14, no. 2, pp. 515–520, 1999.

[44] L. Zhang, Y. Li, C. Y. Guan et al., “Therapeutic effect of human umbilical cord-derived mesenchymal stem cells on injured rat endometrium during its chronic phase,” *Stem Cell Research & Therapy*, vol. 9, no. 1, p. 36, 2018.